Stay updated with breaking news from Hematologic Malignancies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The National Comprehensive Cancer Network 2023 Annual Congress: Hematologic Malignancies returns to San Francisco this week, for the first time since 2019.
/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) 2023 Annual Congress: Hematologic Malignancies™ returns to San Francisco this week, for the...
NCCN 2023 Annual Congress: Hematologic Malignancies features expert perspectives on developments in blood cancer treatment, including NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Updates, CAR T-Cell therapy, BTK Inhibitors, Bispecific T-Cell Engagers, and More. The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square. For full details and to register, visit NCCN.org/hem.
The Committee for Medicinal Products for Human Use has recommended the approval of quizartinib in the European Union for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by maintenance quizartinib, for adult patients with newly diagnosed acute myeloid leukemia.
The addition of quizartinib to induction and consolidation chemotherapy, followed by single-agent quizartinib for up to 36 cycles, improved survival outcomes vs placebo in patients with FLT3 ITD–mutated, newly diagnosed acute myeloid leukemia.